Improving Outcomes and Accelerating Growth--2015 is a Footnote - Sponsored Whitepaper

With $50-70 billion worth of U.S. drug sales at risk due to loss of market exclusivity by blockbuster strategic brands, as pipelines dwindle, and as government and commercial payers drive down costs through generic utilization, enormous costs are at stake. Instead of trying to squeeze business value out of mandated serialization and track-and-trace regulations, how can we drive business benefits through the increased visibility and control that results from tracking systems – thereby making compliance the secondary benefit, and not the driver, of such changes?